The Department of Defense is offering the Alzheimer’s Convergence Science Research Grant to support the generation of research resources and tools in health sciences related to Traumatic Brain Injury (TBI) and Alzheimer’s Disease (AD). This grant aims to address the paucity of research resources and clinical studies focusing on the interrelationship between TBI and AD for military veterans and individuals affected by TBI. The focus areas include genomics, proteomics, bioinformatics, pathology of Tau, and the roles of non-neuronal cells in TBI/AD pathogenesis. Applications involving pharmacologic interventions and drug discovery are not encouraged. The closing date for this grant is January 14, 2015.
Opportunity ID: 264759
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-14-PRARP-CSRA |
| Funding Opportunity Title: | Peer Reviewed Alzheimer’s Convergence Science Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 4 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 11, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jan 14, 2015 |
| Current Closing Date for Applications: | Jan 14, 2015 |
| Archive Date: | Feb 13, 2015 |
| Estimated Total Program Funding: | $2,600,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The PRARP Convergence Science Research Award mechanism was first offered in FY12. Since then, 72 Convergence Science Research Award applications have been received, and 12 have been recommended for funding. The intent of the FY14 CSRA is to support efforts to generate research resources and tools, or novel research efforts for professionals and practitioners in health sciences related to the PRARPs mission. The research impact is intended to benefit the military community, while meeting a public purpose for the benefit of the civilian community. Overarching Challenges: This CSRA funding opportunity requires applications to address one or more of the following PRARP Overarching Challenges: Paucity of Research Resources: The paucity of research resources to examine the interrelationship between TBI and subsequent AD for military Veterans/other individuals affected by TBI. Paucity of Clinical Studies: The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD for military Veterans/other individuals affected by TBI. Diagnostic Technologies, Tests, Interventions, or Devices: The need for technologies, tests, interventions, or devices with the potential to diagnose AD at its earliest stages. Focus Areas: In addition to addressing one or more of the specified Overarching Challenges, applications must also address at least one of the following FY14 PRARP Focus Areas in support of the Overarching Challenges. An application that proposes research outside of these Focus Areas is acceptable, as long as the applicant provides a strong rationale: Genomics/Proteomics/Bioinformatics: Studies or technologies (e.g., genetic, proteomic, and epigenetic strategies) intended to characterize neurological change(s) associated with TBI and subsequent AD. In addition, relevant technologies or tests may be considered under this Focus Area. Pathology of Tau: Novel research and technologies dedicated to unraveling the basic pathological mechanisms of Tau associated with TBI and AD. New! Roles of non-neuronal cells in TBI/AD pathogenesis: Technologies, tests, studies, or devices that will examine the roles of astrocytes (or other non-neuronal cells) in AD neurodegeneration due to TBI. While the CSRA mechanism can be used to support clinical research, the following is specifically discouraged under the FY14 PRARP: Pharmacologic Interventions: Clinical or Basic research requiring investigational or FDA-approved drugs or medicines. Drug Discovery and Development: Clinical or Basic research directly leading to the development of investigational medicines, drugs, or agents. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email:Email: help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 264759 Full Announcement-1 -> PRARP_FY14 CSRA PA_GG.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00205606 | Sep 11, 2014 | Jan 14, 2015 | View |
Package 1
Mandatory forms
264759 RR_SF424_2_0-2.0.pdf
264759 RR_Budget_1_3-1.3.pdf
264759 RR_KeyPersonExpanded_2_0-2.0.pdf
264759 PerformanceSite_2_0-2.0.pdf
Optional forms
264759 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
